Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Reata Pharmaceuticals, Inc. (NASDAQ: RETA).

Full DD Report for RETA

You must become a subscriber to view this report.


Recent News from (NASDAQ: RETA)

Reata Pharmaceuticals' (RETA) CEO Warren Huff on Q1 2018 Results - Earnings Call Transcript
Reata Pharmaceuticals, Inc. (RETA) Q1 2018 Earnings Conference Call May 09, 2018, 08:00 ET Executives Vineet Jindal - IR Warren Huff - Chairman, CEO & President Jason Wilson - CFO & VP of Strategy Colin Meyer - Chief Medical Officer & VP of Product Development An...
Source: SeekingAlpha
Date: May, 13 2018 01:02
Reata Pharmaceuticals beats by $0.79, beats on revenue
Reata Pharmaceuticals (NASDAQ: RETA ): Q1 EPS of $0.15 beats by $0.79 . Revenue of $32.4M (+155.1% Y/Y) beats by $22.34M . Press Release More news on: Reata Pharmaceuticals, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 08 2018 17:35
Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs
CATALYST TRIAL IN CTD-PAH FINAL SAMPLE SIZE SET AT 200; TOP-LINE DATA EXPECTED IN THE FIRST HALF OF 2020 PHOENIX TRIAL INTERIM DATA FOR ADPKD AND IGA NEPHROPATHY COHORTS AT ERA-EDTA IN MAY; FULL DATA FOR THESE COHORTS AND T1D CKD NOW EXPECTED DURING THE THIRD QUARTER OF 2018 C...
Source: GlobeNewswire
Date: May, 08 2018 17:00
Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich's Ataxia and Other Severe Neurological Diseases
IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating that omaveloxolone potently activates the Keap1/Nrf2 pathway, significantly reduces ...
Source: GlobeNewswire
Date: April, 24 2018 16:15
Your Daily Pharma Scoop: Reata Provides Update, Assembly Biosciences Data, Bellicum's BPX-501
A nalysis focus: Reata Pharmaceuticals Today we will discuss Reata Pharmaceuticals ( RETA ), which provided an update on the phase 2 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome. Bardo...
Source: SeekingAlpha
Date: April, 13 2018 08:00
Reata Pharmaceuticals (RETA) CARDINAL Phase 2 Update - Slideshow
The following slide deck was published by Reata Pharmaceuticals in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 12 2018 13:08
Reata Pharma's bardoxolone shows treatment effect in mid-stage portion of Alport syndrome study
Thinly traded small cap Reata Pharmaceuticals (NASDAQ: RETA ) is unchanged after hours on light volume on the heels of its announcement of interim data from the Phase 2 portion of its Phase 2/3 clinical trial, CARDINAL , assessing bardoxolone methyl in patients with chronic kidney disease...
Source: SeekingAlpha
Date: April, 11 2018 16:37
Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
Bardoxolone Treatment Produced Significant Increase in Kidney Function Maintained Through Week 36 Conference Call With Management Scheduled Thursday, April 12 th  at 8:30am ET IRVING, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reat...
Source: GlobeNewswire
Date: April, 11 2018 16:15
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph...
Source: SeekingAlpha
Date: April, 09 2018 13:39
Reata to Present Preclinical Data on RTA 1701, a Novel ROR?t Inverse Agonist, at Upcoming Immunology Conference
Novel, Orally-Bioavailable Agent With Potent Activity in Cell-Based and Animal Models Non-Human Primate Proof-of-Concept for Suppression of IL-17A Achieved Phase 1 Initiation for RTA 1701 Planned in 2018, Initial Results Expected by 1H19 IRVING, Texas, April 03, 2018 (GLOBE NEWS...
Source: GlobeNewswire
Date: April, 03 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1831.9831.5532.6231.11165,269
2018-05-1732.0832.1332.3931.64112,400
2018-05-1630.6532.0232.0930.62199,952
2018-05-1531.4530.6532.4330.06190,979
2018-05-1431.5631.6032.7629.5039208,580

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-218,26420,22940.8522Short
2018-05-1827,20562,18043.7520Short
2018-05-1720,01736,36355.0477Short
2018-05-1635,87971,62750.0914Short
2018-05-1520,97150,92841.1777Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RETA.


About Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Logo for Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $634,911,905 - 05/11/2018
  • Issue and Outstanding: 19,990,929 - 02/28/2018

 


Recent Filings from (NASDAQ: RETA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 10 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 02 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 02 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 01 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: December, 29 2017

 

 


Daily Technical Chart for (NASDAQ: RETA)

Daily Technical Chart for (NASDAQ: RETA)


Stay tuned for daily updates and more on (NASDAQ: RETA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RETA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RETA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of RETA and does not buy, sell, or trade any shares of RETA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/